The two enzymes target different PCR carryover components. Exonuclease I degrades unincorporated single-stranded primers, while shrimp alkaline phosphatase hydrolyzes residual deoxynucleotide triphosphates, or dNTPs. Combining these activities produces a more complete cleanup than addressing only one contaminant, which helps prepare amplified DNA for reliable downstream sequencing and mutation analysis.
Unremoved primers and dNTPs can interfere with subsequent sequencing reactions, potentially reducing the accuracy of results obtained from an amplified DNA product. ExoSAP cleanup removes these residual components before downstream analysis, helping researchers interpret sequence data, mutation calls, or genotyping results with less interference from materials carried over from PCR.
Controlled incubation gives exonuclease I and shrimp alkaline phosphatase time to act on their respective PCR residues. A subsequent enzyme-inactivation step stops their activity before the cleaned amplification product enters downstream analysis. This sequence preserves the intended cleanup while preparing the DNA for uses such as Sanger sequencing or mutation validation.
The workflow begins with an amplified DNA product containing residual primers and dNTPs. The cleanup enzymes are allowed to act during a controlled incubation, after which the enzymes are inactivated. The treated product can then proceed to downstream analysis without the extensive purification steps otherwise used to remove these PCR-associated contaminants.
ExoSAP cleanup is useful when a PCR product must be prepared efficiently for downstream analysis and the main contaminants are unincorporated primers and dNTPs. Because enzymatic treatment addresses these residual components without extensive purification, it can streamline workflows involving Sanger sequencing, mutation analysis, genotyping, and validation of amplification products.
In cancer research, the cleaned PCR product can support characterization of genetic alterations in tumor samples and cancer-related models. By reducing contaminants that may interfere with sequencing reactions, the method contributes to accurate Sanger sequencing, mutation analysis, genotyping, and validation of amplified DNA, helping researchers evaluate cancer-associated genetic changes.